Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Endoscopy

Endoscopy

Endoscopy is a medical procedure that allows healthcare providers to visually examine the interior of the body using a specialized instrument called an endoscope.
This minimally invasive technique is widely used in the diagnosis and treatment of various conditions, particularly those affecting the digestive, respiratory, and urinary systems.
Endoscopic procedures can range from simple examinations to complex interventions, providing valuable insights into the underlying causes of symptoms and enabling targeted therapies.
By utilizing advanced imaging technologies, endoscojes enable healthcare professionals to navigate the body's intricate structures, detect abnormalities, and perform delicate procedures with precision.
This versatile tool has become an indispensable part of modern medicine, empowering clinicians to deliver more effective and personalized care to patients.
Reasearch protocols play a vital role in ensuring the accuracy and reproducibility of endoscopic findings, underscoreing the importance of tools like PubCompare.ai that can streamline the identification and comparison of protocols from a vast array of literature sources.

Most cited protocols related to «Endoscopy»

1
Rosiglitazone for Ulcerative Colitis: A Placebo-Controlled Trial
Data for this study were acquired from a recently completed placebo-controlled randomized trial of rosiglitazone for mild to moderately active ulcerative colitis (clinicaltrials.gov #NCT00065065) which has been described in greater detail previously.7 (link) The trial used a slight modification of the Mayo score to assess disease activity (Table 1). Specifically, the bleeding component as described in the Mayo index was modified such that a score of 3 required both visible blood in 50% or more of bowel movements and at least some bowel movements with blood alone.
The study included 105 patients with mild to moderately active disease defined as a total DAI score of 4 to 10, inclusively. Patients were randomized in a 1:1 ratio to receive either rosiglitazone 4 mg or placebo twice daily for 12 weeks. Disease activity was measured at randomization and every four weeks thereafter until week 12, however lower endoscopy was only completed at week 0 and week 12, such that only a partial Mayo score (9 point scale that excludes the endoscopic appearance of the mucosa) could be calculated at the interim visits. In the very early accrual period of the study, a follow-up visit was included at week 2. Without knowledge of the response rates in either arm, the Data and Safety Monitoring Board (DSMB) requested that the week 2 follow-up evaluation be eliminated with the hopes of minimizing the placebo response rate and maximizing recruitment and retention.6 (link), 8 (link), 9 (link) Eighteen patients completed the week 2 follow-up visit.
During the course of the study, patients could be treated with other conventional medications used to treat active ulcerative colitis including mesalamine, oral corticosteroids, immunomodulators, or topical therapies (mesalamine or corticosteroids) at stable doses. Use of corticosteroids at doses greater than 20mg per day of prednisone or the equivalent was an exclusion criterion. Steroid tapering was not permitted during the study.
In anticipation of this sub-study, at each visit we also included questions about change in disease activity compared to the previous visit and compared to the randomization visit on a global seven-point scale (Table 2). The choices included much better, moderately better, a little better, unchanged, a little worse, moderately worse, and much worse. Patients also graded their current disease activity at each visit on a 6 point Likert scale – perfect, very good (minimal symptoms), good (only mild symptoms), moderately active, moderately severe, or severe. Data on quality of life were measured with the Inflammatory Bowel Disease Questionnaire (IBDQ) authored by Dr. Jan Irvine under license from McMaster University, Hamilton, Canada.10 (link)
Lewis J.D., Chuai S., Nessel L., Lichtenstein G.R., Aberra F.N, & Ellenberg J.H. (2008). Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. Inflammatory bowel diseases, 14(12), 1660-1666.
Publication 2008
Adrenal Cortex Hormones BLOOD Clinical Trials Data Monitoring Committees Defecation Endoscopy Endoscopy, Gastrointestinal Immunologic Adjuvants Inflammatory Bowel Diseases Mesalamine Mucous Membrane Patients Pharmaceutical Preparations Placebos Prednisone Retention (Psychology) Rosiglitazone Steroids Ulcerative Colitis
2
Standardizing Bowel Preparation Evaluation

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Bohring syndrome Cecum Colon Colon, Ascending Colon, Descending Colonoscopy Endoscopy Feces Intestines Left Colic Flexure Mucous Membrane Rectum Sigmoid Colon Transverse Colon Vision
3
Consensus Recommendations on Serrated Lesions
This statement is the result of a two day consensus meeting held in Cleveland in 2010 and sponsored by the National Institutes of Health. The panel members were chosen for their expertise in endoscopy, surgery, pathology, epidemiology, and/or molecular aspects of serrated lesions and/or serrated polyposis. In preparation of this report a literature review was conducted in MEDLINE, 1996 to October, 2011, using the terms hyperplastic polyp, serrated polyp, serrated adenoma, serrated cancer, hyperplastic polyposis syndrome, serrated polyposis syndrome, microsatellite instability, CpG Island Methylator phenotype, and hypermethylation.
The recommendations presented here generally and necessarily reflect expert consensus opinion, as the levels of evidence available to support recommendations are of low or very low quality (20 (link)). The review and recommendations reported here were not commissioned, reviewed, or endorsed by the American College of Gastroenterology.
Rex D.K., Ahnen D.J., Baron J.A., Batts K.P., Burke C.A., Burt R.W., Goldblum J.R., Guillem J.G., Kahi C.J., Kalady M.F., O’Brien M.J., Odze R.D., Ogino S., Parry S., Snover D.C., Torlakovic E.E., Wise P.E., Young J, & Church J. (2012). Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel. The American journal of gastroenterology, 107(9), 1315-1330.
Publication 2012
Adenoma ARID1A protein, human CpG Islands Endoscopy Hyperplasia Malignant Neoplasms Microsatellite Instability Operative Surgical Procedures Phenotype Polyps Syndrome
4
Evaluating Endoscopic Severity in Ulcerative Colitis
Ten specialists in inflammatory bowel disease (IBD, the authors) graded videos of flexible sigmoidoscopy according to their own practice, in the absence of clinical information. Twenty-four representative videos were selected to represent the widest range of UC activity, guided by the Mayo Clinic score (by PK and BRY) from a library of 670 videos recorded in a standard manner during clinical trials for the treatment of moderately active UC6 (link) (EUDRACT 2006-001310-32). Within each Mayo Clinic score stratum, consecutive videos were reviewed by one of the co-authors for image quality. Satisfactory quality recordings (sharp image, sufficient bowel preparation) were selected. Videos from fibreoptic endoscopes were discarded. Sixteen videos represented the complete range of severity; 24 videos enabled choice from additional videos in the mid-range of severity, most likely to be affected by interobserver variation. Each investigator was randomly assigned 16 of the 24 videos in randomised order using a set of Latin squares: a core set of eight videos that all investigators evaluated (two for each Baron score) and eight of 16 non-core videos, This kept the number of evaluations by each investigator in the 2–3 h session to a manageable number (16), while still having a common core set (8) and a broad overall pool of videos (24). Investigators were explicitly advised not to apply the Baron index themselves, to avoid biasing their overall assessment of severity in relation to this index. To assess potential scoring differences based on the length of the video,11 (link) each investigator had two pairs that were shortened from 10–15 min to approximately 5 min, giving a total of 18 videos for each investigator to view. Descriptors of endoscopic severity were selected from previous studies.3 (link)
8 (link)
9 (link)
12 (link)
13 (link) Investigators recorded the presence or absence of 11 descriptors. Overall severity was assessed on a visual analogue scale (VAS, between 0=completely normal and 100=worst ever seen).
To substantiate variability in endoscopic assessment, the level of the Baron index derived from the assessments by investigators was compared with the level assigned by the central reader in the original trial.7 The precise wording of definitions and video clips illustrating anchor points on three-, four- or five-point Likert scales of severity for each descriptor, were subsequently agreed by consensus during a video teleconference between investigators (table 1).
Travis S.P., Schnell D., Krzeski P., Abreu M.T., Altman D.G., Colombel J.F., Feagan B.G., Hanauer S.B., Lémann M., Lichtenstein G.R., Marteau P.R., Reinisch W., Sands B.E., Yacyshyn B.R., Bernhardt C.A., Mary J.Y, & Sandborn W.J. (2011). Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut, 61(4), 535-542.
Publication 2011
BAD protein, human cDNA Library Clip Endoscopes Endoscopy Inflammatory Bowel Diseases Intestines Proctosigmoidoscopy Specialists Vision Visual Analog Pain Scale
5
Colorectal Cancer Epidemiologic Study
We used data from two prospective cohort studies, the Nurses’ Health Study (NHS, involving 121,700 women who were enrolled in 1976) and the Health Professionals Follow-up Study (HPFS, involving 51,500 men who were enrolled in 1986).22 (link),23 (link) Every 2 years, participants were sent follow-up questionnaires to update information on lifestyle factors and to identify newly diagnosed cancers and other diseases. The National Death Index was used to ascertain deaths of study participants. The cause of death was assigned by study physicians. Paraffin-embedded tissue blocks were collected from hospitals where participants with colorectal cancer had undergone colorectal resection or endoscopic biopsy (for preoperatively treated rectal cancer). Tumor-tissue data, information on aspirin use, and survival data were available for 1097 patients with colorectal cancer that was diagnosed before July 1, 2006. Among these patients, we used data from 964 patients for whom information about the presence or absence of PIK3CA mutation, based on analysis of tumor tissue, was available. Patients were followed until death or January 2011, whichever came first.
Written informed consent was obtained from all study participants. Tissue collection and analyses were approved by the human subjects committees at the Harvard School of Public Health and Brigham and Women's Hospital. The last two authors were responsible for the study concept and design. All authors acquired, analyzed, and interpreted the data. The first two authors and the last two authors take responsibility for the integrity of the data and the accuracy of the data analysis and vouch for the fidelity of the study to the protocol.
Liao X., Lochhead P., Nishihara R., Morikawa T., Kuchiba A., Yamauchi M., Imamura Y., Qian Z.R., Baba Y., Shima K., Sun R., Nosho K., Meyerhardt J.A., Giovannucci E., Fuchs C.S., Chan A.T, & Ogino S. (2012). Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. The New England journal of medicine, 367(17), 1596-1606.
Publication 2012
Aspirin Biopsy Colorectal Carcinoma Endoscopy Health Personnel Homo sapiens Malignant Neoplasms Mutation Neoplasms Nurses Paraffin Patients Physicians PIK3CA protein, human Rectal Cancer Tissues Woman

Most recents protocols related to «Endoscopy»

1
Ingestible Device for Ulcerative Colitis Treatment
Not available on PMC !

Example 12

As a proof of concept, the patient population of this study is patients that (1) have moderate to severe ulcerative colitis, regardless of extent, and (2) have had an insufficient response to a previous treatment, e.g., a conventional therapy (e.g., 5-ASA, corticosteroid, and/or immunosuppressant) or a FDA-approved treatment. In this placebo-controlled eight-week study, patients are randomized. All patient undergo a colonoscopy at the start of the study (baseline) and at week 8. Patients enrolled in the study are assessed for clinical status of disease by stool frequency, rectal bleeding, abdominal pain, physician's global assessment, and biomarker levels such as fecal calprotectin and hsCRP. The primary endpoint is a shift in endoscopy scores from Baseline to Week 8. Secondary and exploratory endpoints include safety and tolerability, change in rectal bleeding score, change in abdominal pain score, change in stool frequency, change in partial Mayo score, change in Mayo score, proportion of subjects achieving endoscopy remission, proportion of subjects achieving clinical remission, change in histology score, change in biomarkers of disease such as fecal calprotectin and hsCRP, level of adalimumab in the blood/tissue/stool, change in cytokine levels (e.g., TNFα, IL-6) in the blood and tissue.

FIG. 72 describes an exemplary process of what would occur in clinical practice, and when, where, and how the ingestible device will be used. Briefly, a patient displays symptoms of ulcerative colitis, including but not limited to: diarrhea, bloody stool, abdominal pain, high c-reactive protein (CRP), and/or high fecal calprotectin. A patient may or may not have undergone a colonoscopy with diagnosis of ulcerative colitis at this time. The patient's primary care physician refers the patient. The patient undergoes a colonoscopy with a biopsy, CT scan, and/or MRI. Based on this testing, the patient is diagnosed with ulcerative colitis. Most patients are diagnosed with ulcerative colitis by colonoscopy with biopsy. The severity based on clinical symptoms and endoscopic appearance, and the extent, based on the area of involvement on colonoscopy with or without CT/MRI is documented. Treatment is determined based on diagnosis, severity and extent.

For example, treatment for a patient that is diagnosed with ulcerative colitis is an ingestible device programmed to release a single bolus of a therapeutic agent, e.g., 40 mg adalimumab, in the cecum or proximal to the cecum. Prior to administration of the treatment, the patient is fasted overnight and is allowed to drink clear fluids. Four hours after swallowing the ingestible device, the patient can resume a normal diet. An ingestible device is swallowed at the same time each day. The ingestible device is not recovered.

In some embodiments, there may be two different ingestible devices: one including an induction dose (first 8 to 12 weeks) and a different ingestible device including a different dose or a different dosing interval.

In some examples, the ingestible device can include a mapping tool, which can be used after 8 to 12 weeks of induction therapy, to assess the response status (e.g., based on one or more of the following: drug level, drug antibody level, biomarker level, and mucosal healing status). Depending on the response status determined by the mapping tool, a subject may continue to receive an induction regimen or maintenance regimen of adalimumab.

In different clinical studies, the patients may be diagnosed with Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the cecum, or in both the cecum and transverse colon.

In different clinical studies, the patients may be diagnosed with illeocolonic Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the late jejunum or in the jejunum and transverse colon.

US11857669B2. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices (2024-01-02). BIORA THERAPEUTICS, INC. [US]. Inventors: Mitchell Lawrence Jones [US], Sharat Singh [US], Christopher Loren Wahl [US], Harry Stylli [US].
Full text: Click here
Patent 2024
Abdominal Pain Adalimumab Adrenal Cortex Hormones Biological Markers Biopsy BLOOD Cecum Colonoscopy C Reactive Protein Crohn Disease Cytokine Diarrhea Diet Endoscopy Endoscopy, Gastrointestinal Feces Homo sapiens Immunoglobulins Immunosuppressive Agents Jejunum Leukocyte L1 Antigen Complex Medical Devices Mesalamine Mucous Membrane Neoadjuvant Therapy Patient Care Management Patients Pharmaceutical Preparations Placebos Primary Care Physicians Safety Therapeutics Tissues Transverse Colon Treatment Protocols Tumor Necrosis Factor-alpha Ulcerative Colitis X-Ray Computed Tomography
2
Preoperative Kidney Failure and Surgical Outcomes
We included all adults (≥ 18 years) with an inpatient or ambulatory surgery performed between April 1 2005 and February 28 2019 in Alberta, Canada. Surgeries were identified using the Canadian Classification of Health Interventions (CCI) coding [14 ], which is a standardized coding system for procedures. Radiologic or non-surgical procedures were excluded (e.g., endoscopy, hemodialysis catheter insertion, arteriovenous [AV] fistulogram, etc.). Further, we included only those with preoperative kidney failure, defined as an eGFR < 15 mL/min/1.73m2 or receiving hemodialysis or peritoneal dialysis for at least 90 days as an outpatient before the index surgical procedure. For non-dialysis participants, at least two outpatient measures of serum creatinine between 7–365 days were necessary prior to surgery to avoid misclassification of people with preoperative acute kidney injury, per a validated algorithm [15 (link)]. We estimated eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation without including the Black race coefficient [16 (link)]. We excluded people that left Alberta within 30 days of their surgery, and those without available demographic data.
Harrison T.G., Hemmelgarn B.R., James M.T., Sawhney S., Manns B.J., Tonelli M., Ruzycki S.M., Zarnke K.B., Wilson T.A., McCaughey D, & Ronksley P.E. (2023). Prediction of major postoperative events after non-cardiac surgery for people with kidney failure: derivation and internal validation of risk models. BMC Nephrology, 24, 49.
Full text: Click here
Publication 2023
Adult Ambulatory Surgical Procedures Catheterization Creatinine Dialysis EGFR protein, human Endoscopy Hemodialysis Inpatient Kidney Failure Kidney Injury, Acute Negroes Operative Surgical Procedures Outpatients Peritoneal Dialysis Serum
3
Surgical Procedures Database Analysis
Categories of common surgical purposes and procedures were set across the fields and included transplantation surgery, trauma surgery, surgical oncology (operations of malignant disease), endoscopic and minimum invasive surgery, including robot-assisted surgery, and the number of corresponding programs were counted. As an example of advanced medical technologies, mediastinoscopic radical esophagectomy for esophageal cancer [5 (link)–7 (link)], transanal minimally invasive surgery (TAMIS) and transanal total mesorectal excision (TaTME) for rectal cancer [8 (link), 9 (link)], laparoscopic pancreaticoduodenectomy (Lap-PD) for pancreatic lesions [10 (link)], and minimally invasive cardiac surgery (MICS) for cardiovascular lesions [11 (link)] were selected, and their numbers were counted.
Shichinohe T., Date H., Hatano E., Kobayashi E., Hiramatsu M., Hirano S., Izawa Y, & Shirakawa Y. (2023). Cadaver surgical training and research using donated cadavers in the field of surgery in Japan: an overview of reports from 2012 to 2021. Surgery Today.
Publication 2023
Cardiovascular System Endoscopy Esophageal Cancer Esophagectomy Heart Laparoscopy Malignant Neoplasms Mediastinoscopy Minimally Invasive Surgical Procedures Operative Surgical Procedures Pancreas Pancreaticoduodenectomy Proctectomy Robotic Surgical Procedures Transanal Minimally Invasive Surgery Transplantation Wounds and Injuries
4
Multicenter Retrospective Analysis of FMT for IBD
In all centres, patients undergoing FMT treatment were registered prospectively. Data about IBD outcome and long-term follow-up were in part collected retrospectively (Supplemental Figure 1).
Data collection was performed by each centre using files of the FMT services and hospital records for the patients. If possible, patients were contacted directly. The following baseline characteristics were collected: age, gender, and the use of PPIs. The following data about the CDI were collected: number of episodes; diagnostics by polymerase chain reaction or toxin enzyme immunoassay; and information about previous treatment with metronidazole, vancomycin, fidaxomicin, or bezlotoxumab. Severe CDI was defined as leukocytes ⩾15 × 109/L and/or a 50% increase in creatinine at baseline.17 (link) FMT data included the pre-treatment regimen (antibiotics, bowel lavage), total number of FMTs needed per patient, the route of administration of FMT, and the total amount of faeces (grams) used for preparation of the suspensions or capsules that were administered per patient. Data about clinical recurrence and microbiological testing for CDI after FMT were collected at 8–12 weeks after FMT. Long-term follow-up data of CDI recurrence were included if available.
For IBD, information was collected about the diagnosis according to the Montreal classification and the disease duration. Previous and current IBD medication at the moment of FMT and the use of immunosuppressive medication (including corticosteroids and budesonide, immunomodulators and biologicals) was assessed. Both at baseline and 8 weeks after FMT, the presence of an IBD flare was based on information from the treating physician and/or endoscopic scores. In case of a concomitant flare, remission-induction therapy was defined as the use of prednisolone or budesonide at the moment of FMT, or recently initiated antitumor necrosis factor (TNF) treatment (⩽2 months before FMT). Also haemoglobin (mmol/l) and C-reactive protein (mg/l) in the blood and the calprotectin (µg/g) in the faeces were collected at baseline and after 8 weeks.
The long-term follow-up period per patient was calculated from the date of FMT up to 31 December 2020. Long-term follow-up data included information about possibly occurring events and if yes, the number of days after FMT it occurred. Possible occurring events, collected via patient recall or from hospital records, were as follows: a recurrence of CDI, the development of an IBD flare, general infection and antibiotic use, hospital admission, colectomy, and occurrence of death.
van Lingen E.(., Baunwall S.(., Lieberknecht S.(., Benech N.(., Ianiro G.(., Sokol H.(., Gasbarrini A.(., Cammarota G.(., Eriksen M.(., van der Meulen-de Jong A.(., Terveer E.(., Verspaget H.(., Vehreschild M.(., Hvas C.(, & Keller J.(. (2023). Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 16, 17562848231156285.
Publication 2023
Adrenal Cortex Hormones Antibiotics bezlotoxumab Biological Factors BLOOD Budesonide Capsule Colectomy C Reactive Protein Creatinine Diagnosis Endoscopy Enzyme Immunoassay Feces Fidaxomicin Gender Hemoglobin Immunologic Adjuvants Immunosuppressive Agents Intestines Leukocyte L1 Antigen Complex Leukocytes Mental Recall Metronidazole Necrosis Neoadjuvant Therapy Patients Pharmaceutical Preparations Physicians Polymerase Chain Reaction Prednisolone Prepulse Inhibition Recurrence Remission Induction Sepsis Toxins, Biological Treatment Protocols Vancomycin
5
ICU Patients' Swallowing Disorder Risk Factors
The inclusion criteria were as follows.
Participating population: patients were admitted to the ICU and mechanically ventilated. Age ≥ 18.
Intervention/exposure: Post-extubation dysphagia.
Comparison/control: Non-post-extubation dysphagia.
Outcome: Risk factors for post-extubation dysphagia.
Type of study: The study is observational, either cross-sectional, cohort, or case–control; use of 1 or more swallowing disorder assessment tools. Example: fiberoptic endoscopic evaluation of swallowing, video fluoroscopy swallow study, Bogenhausen Dysphagia Score, water swallow test (WST); bedside swallowing evaluation; clinical swallowing evaluation, and Sydney Swallowing Questionnaire.
The following types of records were excluded: replicated study data; incomplete data; non-original studies (conference abstracts, editorials, letters, reviews, meta-analyses, commentaries, or case reports).
Hou L., Li Y., Wang J., Wang Y., Wang J., Hu G, & Ding X.R. (2023). Risk factors for post-extubation dysphagia in ICU: A systematic review and meta-analysis. Medicine, 102(10), e33153.
Publication 2023
Conferences Deglutition Disorders Endoscopy Fluoroscopy Patients Tracheal Extubation

Top products related to «Endoscopy»

1
Gif h260 by Olympus
Sourced in Japan
The GIF-H260 is a high-performance laboratory equipment designed for general-purpose applications. It features a compact and durable construction, offering reliable performance. The device's core function is to provide a stable and controlled environment for various laboratory procedures.
2
Gif h260z by Olympus
Sourced in Japan, United Kingdom
The GIF-H260Z is a versatile laboratory equipment designed for a range of scientific applications. It features a high-resolution optical system and advanced imaging capabilities to support detailed analysis and observation tasks. The core function of the GIF-H260Z is to provide users with a reliable and precise tool for their research and testing needs.
3
Gif q260j by Olympus
Sourced in Japan, United Kingdom, Germany
The GIF-Q260J is a laboratory equipment product from Olympus. It is designed to perform a core function, but the specific details of its intended use are not available in this concise, unbiased, and factual description.
4
Gif q260 by Olympus
Sourced in Japan, United Kingdom
The GIF-Q260 is a high-precision laboratory equipment designed for advanced imaging and analysis applications. It features a state-of-the-art imaging sensor and advanced optical components to provide detailed, high-resolution images. The core function of the GIF-Q260 is to capture and process visual data for scientific and research purposes.
5
Vio300d by Erbe
Sourced in Germany, United States, Japan
The VIO300D is a high-performance electrosurgical generator. It is designed for use in a variety of surgical procedures, providing precise control and consistent cutting and coagulation performance.
6
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
7
Gif h290 by Olympus
Sourced in Japan
The GIF-H290 is a high-quality laboratory microscope camera designed for capturing clear and detailed images. It features a 29-megapixel sensor and supports a variety of image formats, including GIF, JPEG, and TIFF. The camera is compatible with a range of microscopes and is suitable for a variety of scientific applications.
8
Gif h290z by Olympus
Sourced in Japan
The GIF-H290Z is a high-performance laboratory microscope designed for a variety of scientific applications. It features a sturdy and durable construction, ensuring reliable performance in research and testing environments. The microscope offers advanced optics and illumination systems for clear and detailed observations.
9
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
10
Rnalater by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Japan, Lithuania, Italy, Australia, Canada, Denmark, China, New Zealand, Spain, Belgium, France, Sweden, Switzerland, Brazil, Austria, Ireland, India, Netherlands, Portugal, Jamaica
RNAlater is a RNA stabilization solution developed by Thermo Fisher Scientific. It is designed to protect RNA from degradation during sample collection, storage, and transportation. RNAlater stabilizes the RNA in tissues and cells, allowing for efficient RNA extraction and analysis.

More about "Endoscopy"

Endoscopic procedures, minimally invasive diagnostics, GI endoscopy, respiratory endoscopy, urinary endoscopy, endoscopic imaging, endoscope, VIO300D, GIF-H260, GIF-H260Z, GIF-Q260J, GIF-Q260, GIF-H290, GIF-H290Z, SAS 9.4, SAS version 9.4, RNAlater, protocol research, procedure reproducibility.
Endoscopy is a versatile medical technique that allows healthcare providers to visually examine the interior of the body using a specialized instrument called an endoscope.
This minimally invasive approach is widely used in the diagnosis and treatment of various conditions, particularly those affecting the digestive, respiratory, and urinary systems.
Endoscopic procedures can range from simple examinations to complex interventions, providing valuable insights into the underlying causes of symptoms and enabling targeted therapies.
Endoscopic imaging technologies, such as the GIF-H260, GIF-H260Z, GIF-Q260J, GIF-Q260, GIF-H290, and GIF-H290Z endoscopes, empower clinicians to navigate the body's intricate structures, detect abnormalities, and perform delicate procedures with precision.
The VIO300D electrosurgical unit and SAS 9.4 (or SAS version 9.4) statistical software can also be integrated into endoscopic workflows, enhancing data analysis and research capabilities.
Reasearch protocols play a vital role in ensuring the accuracy and reproducibility of endoscopic findings, underscoreing the importance of tools like PubCompare.ai that can streamline the identification and comparison of protocols from a vast array of literature sources, including pre-prints and patents.
By harnessing the power of comparison, researchers can identify the most accurate and reproducible protocols, ensuring their endoscopy research is rock-solid.
Explore the versatility and power of endoscopy in modern medicine, and discover how PubCompare.ai can streamline your endoscopy research workflow.